Working… Menu

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01312935
Recruitment Status : Terminated (PolyMedix decided to stop enrollment in both clinical trials due to observations of reductions in blood pressure.)
First Posted : March 11, 2011
Last Update Posted : May 17, 2012
Information provided by (Responsible Party):
PolyMedix, Inc.

Brief Summary:
The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Condition or disease Intervention/treatment Phase
Percutaneous Coronary Intervention Coronary Artery Disease (CAD) Angioplasty Drug: PMX-60056 Phase 2

Detailed Description:
PMX-60056 is being developed as a rapid and effective reversal agent for use in those situations where anticoagulation by heparin, or LMWH must be quickly stopped. Potential uses include reversal of anticoagulation induced to prevent clotting during surgical procedures, and rescue from cases of inadvertent or unexpected overdose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Proof of Concept Study of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Study Start Date : April 2011
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: Heparin and PMX-60056 Drug: PMX-60056
investigational drug

Primary Outcome Measures :
  1. The primary outcome measure of this study is the ability to reverse the anticoagulant effects of heparin (as measured by ACT) to the same extent as is known for protamine. intravenous infusion of PMX-60056. [ Time Frame: Immediately post completion of PCI procedure, until 2 hours after last dose. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The patient will undergo PCI for diagnostic and/or therapeutic purposes with a procedure that uses anticoagulation before the instrumentation and reversal of anticoagulation immediately after the procedure.
  2. Male or female patients of any race, aged 18-80 years old.
  3. The patient will be anti-coagulated with unfractionated heparin.
  4. The patient is medically stable and physically and mentally able to participate in this study.
  5. The patient has given written informed consent to participate in this study after fully understanding the implications and constraints of the protocol.

Exclusion Criteria:

  1. The patient requires emergency surgery under conditions which prevent compliance with this protocol or which might cause unacceptable risk to the patient.
  2. The patient requires any concomitant surgical procedures (e.g., carotid artery, CABG) during the PCI.
  3. The patient has received any investigational drug within 30 days of study enrollment, or has had any prior exposure to PMX-60056.
  4. The patient has any condition or abnormality which may, in the opinion of the Investigator, compromise the safety of the patient.
  5. The patient is pregnant or breast feeding.
  6. The patient is of childbearing potential and not under adequate contraceptive protection.
  7. The patient has a history of clinically significant hematologic disease including heparin-induced thrombocytopenia, bleeding disorders, or platelet count <100,000.
  8. Severe impaired hepatic function (SGOT, SGPT >2 x ULN).
  9. History of AIDS, ± HIV.
  10. History of allergy to heparin (beef or pig), protamine, or salmon.
  11. History of chronic alcohol or drug abuse within the last one year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01312935

Layout table for location information
United States, Indiana
South Bend, Indiana, United States
United States, Michigan
Detroit, Michigan, United States
United States, South Dakota
Rapid City, South Dakota, United States
Sponsors and Collaborators
PolyMedix, Inc.
Layout table for additonal information
Responsible Party: PolyMedix, Inc. Identifier: NCT01312935    
Other Study ID Numbers: PMX56-203
First Posted: March 11, 2011    Key Record Dates
Last Update Posted: May 17, 2012
Last Verified: May 2012
Keywords provided by PolyMedix, Inc.:
Percutaneous Coronary Intervention
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases